HOME >> BIOLOGY >> NEWS
Studies offer data on potential impact of Reminyl on caregiver 'burden' in Alzheimer's disease

r greater of patients included nausea, vomiting, anorexia, diarrhea and weight loss.

Reminyl is available by prescription in 4 mg, 8 mg or 12 mg tablets, as well as in an oral solution (4mg/ml). It should be taken by patients twice a day, preferably with morning and evening meals. It is recommended that physicians start by prescribing 8 mg of Reminyl per day (in two divided doses) for at least four weeks, then increase to the recommended maintenance dose of 16 mg per day. Physicians have the flexibility to increase the daily dose to 24 mg after an additional four weeks. More information on the product, including full prescribing information, can be found at www.reminyl.com.

About Reminyl

Reminyl was first approved in Sweden in March of 2000, for the treatment of mild to moderate Alzheimers disease. It is believed that Reminyl inhibits an enzyme that breaks down acetylcholine a chemical in the brain that plays a key role in memory and learning. It also is believed that Reminyl modulates the brains nicotinic receptors, to which acetylcholine binds. Laboratory research suggests that through this modulation, Reminyl stimulates greater release of acetylcholine. Research designed to define the significance of this finding in humans is underway.


'"/>

Contact: Andrew Cooper
andrew.cooper@ketchum.com
44-020-7611-3859
Ketchum
13-Sep-2001


Page: 1 2 3 4

Related biology news :

1. Monkey business: Studies show tiny callimicos have unusual characteristics
2. Studies show success of Mectizan partnerships
3. Studies offer new insight into HIV vaccine development
4. Studies suggest brain injury results from developmental exposure to alcohol, anesthesia, and lead
5. Studies show preventive value of food supplements
6. Studies probe rapid evolution of Chinese tallow trees
7. Studies of rare blood syndrome yield novel route to cancer
8. Studies dispute ultraviolet effect on amphibian population declines
9. Studies of spiders silk reveal unusual strength
10. Studies of genes in mice and common worm may accelerate research on blood diseases, cancers
11. Studies: Floyd, other major hurricanes of 99 caused significant changes in nations largest lagoonal estuary

Post Your Comments:
(Date:8/5/2015)... According to a new market ... Services, Vertical (BFSI, Airport, IT & Telecom, Utilities, Education, ... to 2020", published by MarketsandMarkets, defines and segments the ... segments. The global PIAM Market is estimated to grow ... 2019, at a CAGR of 14.9 % from 2014 ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors ... growth in applications, penetration into newer sectors, and development ... The global biosensors space has seen the entry of ... market so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ... Sullivan, Analysis of the Global Biosensors Market ...
(Date:8/4/2015)... AMRI ) today reported financial and operating results for the ... Second quarter contract revenue of $ 85.2 ... contract margins of 26 % , Second ... EPS from royalties in the current quarter , ... very pleased to present another strong financial quarter, with all our ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
(Date:8/31/2015)... , Aug. 31, 2015  RXi Pharmaceuticals Corporation ... on discovering and developing innovative therapies primarily in ... that the 30-day review period following the filing ... ocular indications with the U.S. Food and Drug ... now active. Logo -  ...
(Date:8/31/2015)... Trimb Healthcare AB ("Trimb") today announced that it has ... a Dutch OTC company with operations in key European ... 16 million, with solid growth and leading brands in ... build a leading international OTC company, and this acquisition ... us a stronger North European OTC platform, from which ...
(Date:8/30/2015)... England , August 31, 2015 ... Wartezeit   einer Frau   für chirurgische   Behandlung ... Alter von 7-90   werden für eine   ... soll 1200 Frauen behandeln und die Anzahl ausgebildeter Chirurgen ... Astellas gab heute bekannt, dass  Action on ...
(Date:8/28/2015)... Aug. 28, 2015 /PRNewswire/ - RepliCel Life Sciences ... medicine company focused on the development of autologous ... quarter ended June 30, 2015, corporate highlights, and ... report are available at www.sedar.com ,  ... "RepliCel expects to launch its RCS-01 ...
Breaking Biology Technology:RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5
Cached News: